Arlene Weintraub
Arlene is Xconomy's east coast biotechnology editor and the editor of Xconomy New York. She is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
Recent posts
-
On June 1, cancer scientists and drugmakers will flock to Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO). The gathering is so prominent that many pharmaceutical... Read more »
-
At first glance, the $1.1 million financing announced by Halo Therapeutics on Tuesday looked like your average case of a biotech startup scraping together enough money to get its early-stage compound into... Read more »
-
Today Ra Pharmaceuticals CEO Doug Treco will make a presentation at a conference in Las Vegas that will cap off the Cambridge, MA-based company’s weeklong unveiling. On May 16, Ra announced it had... Read more »
-
On April 2, shares of New York-based Keryx Pharmaceuticals (NASDAQ: KERX) fell a stomach-churning 65 percent to $1.74 after the company announced that a late-stage trial of its colon cancer drug failed.... Read more »
-
A few years back, molecular geneticist Tom Maniatis was approached by a Harvard Business School student with a heart-wrenching story. The student, Avichai Kremer, then 29, had been diagnosed with amyotrophic lateral sclerosis... Read more »
-
Biotech firm Promedior announced today that it will be moving its headquarters from Malvern, PA, to Boston, and that it has hired a new CEO, Suzanne Bruhn,who was previously senior vice president... Read more »
-
New York-based Lenddo, which uses social media to help middle-class folks in emerging countries secure loans, announced today that it has raised $8 million in a Series A funding round. Investors include Accel Partners,... Read more »
-
In March, global consulting firm Ernst & Young released an annual report for its life sciences clients called “The Third Place: Healthcare Everywhere.” It discusses a range of topics, from apps designed... Read more »
-
On Wednesday, New York-based Center for an Urban Future, a policy think tank, released a report surveying the city’s digital startup scene, and its conclusion was rather dramatic: New York has surpassed Boston... Read more »
-
When the Cancer Research Institute was founded in 1953 in New York, it set out to pursue an idea that was radical at the time—the notion that mobilizing the body’s innate... Read more »
-
Cambridge, MA-based Eleven Biotherapeutics said today that it has expanded its Series A financing by $20 million, bringing the total raised in the funding round to $45 million. New investor JAFCO joined... Read more »
-
New York-based biotech company Retrophin announced this morning that it has completed a $4 million Series A round led by MSMB Capital, a life sciences hedge fund based in New York. Both MSMB... Read more »
-
Yesterday at the New York Biotechnology Association’s 21st annual meeting, National Institutes of Health director Francis Collins was beamed in by videoconference to a keynote lunch at the Times Square Marriott Marquis.... Read more »
-
Last night, just hours after New York drug giant Pfizer (NYSE: PFE) reported first-quarter profits that suffered from generic competition on its blockbuster cholesterol drug atorvastatin (Lipitor), the company announced... Read more »
-
Michael Nusbaum rarely thought twice about giving his personal cell phone number to patients after he operated on them. Nusbaum is a bariatric surgeon at New Jersey’s Morristown Medical Center, and he... Read more »
-
Cambridge, MA-based Mersana Therapeutics is working in one of the hottest areas of biotech research—it’s figuring out new ways to attach potent anti-cancer drugs to specialized molecules that deliver the medicine... Read more »
-
The New York eHealth Collaborative announced yesterday that it has created a new incubator, called the New York Digital Health Accelerator. The program, which is now accepting applications for its first class... Read more »
-
Cambridge, MA-based Epizyme said today that it has formed a strategic partnership with an international subsidiary of Summit, NJ-based Celgene (NASDAQ: CELG). The two companies will work together to develop targeted... Read more »
-
Drug development is never easy for cash-strapped biotechs, but for those wanting to make new drugs to treat diabetes—where the FDA demands clinical trials that are long and expensive—it can be... Read more »
-
One of the most closely watched developments in the quest for new multiple sclerosis treatments is the experimental drug alemtuzumab (Lemtrada) from Cambridge, MA-based Genzyme, a unit of French drug giant Sanofi (NYSE:... Read more »
